Protein kinases — the major drug targets of the twenty-first century?

By P. Cohen. Nature reviews. Drug discovery, 2002

1,979 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/5c7022fbc17b62c326f9cda5131d4c49e6765b92

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Molecular Biology

Citations in the corpus

Pharmacological inhibitors of glycogen synthase kinase 3. (2004, background): “Because many diseases are associated with abnormalities of protein phosphorylation, pharmacological inhibitors of kinases and phosphatases have become a major interest in drug discovery [ 1 ,2].”
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors (2007, background): “Protein kinases represent an important class of drug targets, particularly in oncology and inflammatio”
Quantitative Phosphoproteomics Applied to the Yeast Pheromone Signaling Pathway*S (2005, background): “differentiation are governed by reversible phosphorylation at specific serine, threonine, and tyrosine residues in proteins, and protein kinases and phosphatases are becoming major drug targets for a wide variety of diseases (4).”
Reconstruction of cellular signalling networks and analysis of their properties (2005, background): “Stoichiometric signalling network reconstructions are likely to drive structural and dynamic network analyses and therefore lead to predictions of systems-level behaviour that will be important for future biochemical and medical researc”
Calmodulin kinase II inhibition protects against structural heart disease (2005, background): “Discussion Protein kinases are a rapidly emerging drug target class that may complement and add specificity of action to a large number of 'conventional' drugs targeted to G-protein-coupled receptor”
The specificities of protein kinase inhibitors: an update. (2003, neutral): “We have previously examined the specificities of 28 commercially available compounds, reported to be relatively selective inhibitors of particular serine}threonine-specific protein kinases [Davies, Reddy, Caivano and Cohen (2000) Biochem.”